This study is to determine the feasibility of administering neoadjuvant carboplatin,
paclitaxel, and bevacizumab without excessive dose modification or cycle delay in patients
with epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. This
study will also investigate the rate of optimal cytoreduction, response rate and progression
free and overall survival, and to assess the quality of life for patients with epithelial
ovarian cancer, primary peritoneal cancer or fallopian tube cancer treated with neoadjuvant
carboplatin, paclitaxel and bevacizumab.